CytoDyn study of leronlimab for COVID-19 passes first safety review

• The independent Data Safety Monitoring Committee (DSMC) has completed its first interim analysis of a Phase 2b/3 clinical trial evaluating CytoDyn's (OTCQB:CYDY) leronlimab in severe-to-critical COVID-19 patients. The analysis was performed on data from the first 50% (n=195) of participants.
• The DSMC recommends that the study continue unchanged.
• The next safety review will be conducted when enrollment reaches 75% (n=293).
• Full enrollment (n=390) should be achieved before year-end.
• https://seekingalpha.com/news/3623549-cytodyn-study-of-leronlimab-for-covidminus-19-passes-first-safety-review